Sequence diversity of the factor H binding protein vaccine candidate in epidemiological relevant strains of serogroup B neisseria meningitidis

Journal of Infectious Diseases

Volumn 200, Issue 3, 2009, Pages 379-389

  Murphy, Ellen ^a   Andrew, Lubomira ^a   Lee, Kwok Leung ^a   Dilts, Deborah A ^a   Nunez, Lorna ^a   Fink, Pamela S ^a   Ambrose, Karita ^a   Borrow, Ray ^d   Findlow, Jamie ^d   Taha, Muhamed Kheir ^e   Deghmane, Ala Eddine ^e   Kriz, Paula ^f   Musilek, Martin ^f   Kalmusova, Jitka ^f   Caugant, Dominique A ^g   Alvestad, Torill ^g   Mayer, Leonard W ^a,b   Sacchi, Claudio T ^a,b,h   Wang, Xin ^a,b   Martin, Diana ⁱ   Von Gottberg, Anne ^j   Plessis, Mignon Du ^j   Klugman, Keith P ^c,j   Anderson, Annaliesa S ^a   Jansen, Kathrin U ^a   Zlotnick, Gary W ^a   Hoiseth, Susan K ^a   more..

^a WYETH RESEARCH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c EMORY UNIVERSITY   (United States)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e INSTITUT PASTEUR   (France)

^f NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^g NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^h INSTITUTO ADOLFO LUTZ   (Brazil)

ⁱ INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^j NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; FACTOR H BINDING PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; EUROPE; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC VARIATION; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MOLECULAR SEQUENCE DATA; NEISSERIA MENINGITIDIS, SEROGROUP B; NEW ZEALAND; SOUTH AFRICA; UNITED STATES;

EID: 67650691544     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/600141     Document Type: Article

References (40)

1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88.
2. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7.
3. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138:4402-7.
4. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2:355-7.
5. Farley J, Fletcher L, Bernfield L, et al. Characterization, cloning and expression of different subfamilies of the ORF 2086 gene from Neisseria meningitidis. In: Program and abstracts of the 13th International Pathogenic Neisseria Conference (Oslo, Norway). 2002.
6. Bernfield L, Fletcher L, Howell A, et al. Identification of a novel vaccine candidate for group B Neisseria meningitidis. In: Program and abstracts of the 13th International Pathogenic Neisseria Conference (Oslo, Norway). 2002.
7. Fletcher LD, Bemfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72:2088-100.
8. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197:789-99.
9. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006; 177:501-10.
10. Granoff DM, Welsch JA, Ram S. Binding of complement Factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 2009; 77: 764-9.
11. Schneider MC, Exley RM, Chan H, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006; 176:7566-75.
12. Haralambous E, Dolly SO, Hibberd ML, et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 2006; 38: 764-71.
13. Welsch JA, Ram S, Koeberling O, Granoff DM. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 2008; 197:1053-61.
14. Nissen MD, Marshall HS, Richmond P, et al. A randomized, placebocontrolled, double-blind, phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine. In: Program and abstracts of the 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (Graz, Austria). 2008.
15. von Gottberg A, du Plessis M, Cohen C, et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 2008; 46:377-86.
16. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance. Available at: http://www.cdc.gov/ncidod/dbmd/abcs/ meth-surv-pop.htm. Accessed 8 June 2009.
17. Rouaud P, Perrocheau A, Taha MK, et al. Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005. Euro Surveillance 2006; 11:178-81.
18. Jolley KA, Chan MS, Maiden MC. mlstdbNet-distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics 2004; 5:86.
19. Chenna R, Sugawara H, Koike T, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003; 31:3497-500.
20. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987; 4:406-25.
21. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980; 16:111-20.
22. Rice P, Longden I, Bleasby A. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 2000; 16:276-7.
23. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24:1596-9.
24. Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies. Mol Biol Evol 2006; 23:254-67.
25. Holmes EC, Urwin R and Maiden MC. The influence of recombination on the population structure and evolution of the human pathogen Neisseria meningitidis. Mol Biol Evol 1999; 16:741-9.
26. Mascioni A, Bentley BE, Camarda R, et al. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J Biol Chem 2009; 284:8738-16.
27. Diermayer M, Hedberg K, Hoesly F, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET5 strain. JAMA 1999; 281:1493-7.
28. Yazdankhah SP, Kriz P, Tzanakaki G, et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004; 42:5146-53.
29. Pillai S, Howell A, Alexander K, et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 2005; 23: 2206-9.
30. Jiang H-Q, Harris SL, Tan C, et al. Prediction of broad vaccine coverage for a bivalent rLP2086 based vaccine which elicits serum bactericidal activity agains a diverse collection of serogroup B meningococci. In: Program and abstract of the 16th International Pathogenic Neisseria Conference (Rotterdam, The Netherlands). 2008.
31. Anderson AS, Xu R, Tan C, et al. Functional cross-reactive antibodies are elicited by a Group B Neisseria meningitidis bivalent recombinant lipidated LP2086 vaccine in Cynomolgus macaques [abstract P100]. In: Program and abstract of the 16th International Pathogenic Neisseria Conference (Rotterdam, The Netherlands). 2008.
32. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 2007; 195:1472-9.
33. Jacobsson S, Thulin S, Molling P, et al. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 2006; 24:2161-8.
34. Halperin SA, Langley JM, Smith B, et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 2007; 25:450-7.
35. Rokbi B, Mignon M, Caugant DA , Quentin-Millet MJ. Heterogeneity of tbpB, the transferrin-binding protein B gene, among serogroup B Neisseria meningitidis strains of the ET-5 complex. Clin Diagn Lab Immunol 1997; 4:522-9.
36. Tondella ML, Popovic T, Rosenstein NE, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol 2000; 38:3323-8.
37. Sacchi CT, Whitney AM, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000; 182:1169-76.
38. Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate ofNeisseria meningitidis. J Exp Med 2002; 195:1445-54.
39. Koeberling O, Giuntini S, Seubert A, Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express Factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 2009; 16:156-62.
40. McNeil LK, Murphy E, Zhao X-J, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009; 27:3417-21.